Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy
Allogeneic Therapy Can Be Re-Dosed
Executive Summary
Nkarta has updated its early results for its natural killer cell therapy, where it has shown promising efficacy and potentially superior safety to existing CAR-Ts.
You may also be interested in...
Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
Editas Slims Down To Focus On Gene-Editing Sickle Cell Therapy Race
Editas is seen as a slow developer in the CRISPR-based therapeutics field compared with its rivals but its new CEO has unveiled a new strategy to speed progress.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.